MARLISSA

MARLISSA- levonorgestrel and ethinyl estradiol
A-S Medication Solutions

Rx Only

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including MARLISSA® , are contraindicated in women who are over 35 years of age and smoke [see CONTRAINDICATIONS and WARNINGS (1)].

DESCRIPTION

MARLISSA® (levonorgestrel and ethinyl estradiol tablets) is a combination oral contraceptive (COC) consisting of 21 light-orange to orange color MARLISSA ® (levonorgestrel and ethinyl estradiol tablets), each containing 0.15 mg of levonorgestrel USP, a totally synthetic progestogen, and 0.03 mg of ethinyl estradiol USP, an estrogen and 7 light pink to pink inert tablets (without hormones).

The structural formulas for the active components are:

chemical-structure-levo

Levonorgestrel USP

C21 H28 O2 MW: 312.4

Levonorgestrel USP is chemically d(-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one

chemical-structure-ee

Ethinyl Estradiol USP

C20 H24 O2 MW: 296.4

Ethinyl Estradiol is 19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3, 17-diol.

Each light orange to orange color active tablet contains the following inactive ingredients: FD&C Yellow 6, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polacrilin potassium, povidone and talc.

Each light pink to pink inert tablet contains the following inactive ingredients: D&C Red 30, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polacrilin potassium, povidone and talc.

Each orange tablets contains FD&C yellow No. 6 as a color additive.

CLINICAL PHARMACOLOGY

Combination oral contraceptives prevent pregnancy primarily by suppressing ovulation.

INDICATIONS AND USAGE

MARLISSA® (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy.

CONTRAINDICATIONS

MARLISSA® (levonorgestrel and ethinyl estradiol tablets) is contraindicated in females who are known to have the following conditions:

A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:
Smoke, if over age 35 [see BOXED WARNING and WARNINGS (1) ].
Have current or history of deep vein thrombosis or pulmonary embolism [see WARNINGS (1)].
Have cerebrovascular disease [see WARNINGS (1)].
Have coronary artery disease [see WARNINGS (1)].
Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see WARNINGS (1)].
Have inherited or acquired hypercoagulopathies [see (1)].
Have uncontrolled hypertension or hypertension with vascular disease [see WARNINGS(3)].
Have diabetes mellitus and are over age 35, diabetes mellitus with hypertension or vascular disease or other end-organ damage, or diabetes mellitus of >20 years duration [see WARNINGS (7)].
Have headaches with focal neurological symptoms, migraine headaches with aura, or over age 35 with any migraine headaches [see WARNINGS (8)].
Current or history of breast cancer or other estrogen- or progestin-sensitive cancer.
Liver tumors, acute viral hepatitis, or severe (decompensated) cirrhosis [see WARNINGS (2)].
Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see WARNINGS (5)].
Undiagnosed abnormal uterine bleeding [see WARNINGS (9)].
Pregnancy, because there is no reason to use COCs during pregnancy [see PRECAUTIONS (6)].

WARNINGS

1. Thromboembolic Disorders and Other Vascular Conditions

Stop MARLISSA® (levonorgestrel and ethinyl estradiol tablets) if an arterial or venous thrombotic/thromboembolic event occurs.
Stop MARLISSA® (levonorgestrel and ethinyl estradiol tablets) if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions and evaluate for retinal vein thrombosis immediately.
Discontinue MARLISSA® (levonorgestrel and ethinyl estradiol tablets) during prolonged immobilization. If feasible, stop MARLISSA® at least four weeks before and through two weeks after major surgery, or other surgeries known to have an elevated risk of thromboembolism.
Start MARLISSA® (levonorgestrel and ethinyl estradiol tablets) no earlier than four weeks after delivery in females who are not breast-feeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the likelihood of ovulation increases after the third postpartum week.
Before starting MARLISSA® (levonorgestrel and ethinyl estradiol tablets) evaluate any past medical history or family history of thrombotic or thromboembolic disorders and consider whether the history suggests an inherited or acquired hypercoagulopathy. MARLISSA® (levonorgestrel and ethinyl estradiol tablets) is contraindicated in females with a high risk of arterial or venous thrombotic/thromboembolic diseases (see CONTRAINDICATIONS).

Arterial Events

COCs increase the risk of cardiovascular events and cerebrovascular events, such as myocardial infarction and stroke. The risk is greater among older women (> 35 years of age), smokers, and females with hypertension, dyslipidemia, diabetes, or obesity.

MARLISSA® (levonorgestrel and ethinyl estradiol tablets) is contraindicated in women over 35 years of age who smoke (see CONTRAINDICATIONS). Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked.

Venous Events

Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs (see CONTRAINDICATIONS). While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman-years.

The risk of VTE is highest during the first year of use of a COC and when restarting hormonal contraception after a break of four weeks or longer. Based on results from a few studies, there is some evidence that this is true for non-oral products as well. The risk of thromboembolic disease due to COCs gradually disappears after COC use is discontinued.

Figure 1 shows the risk of developing a VTE for females who are not pregnant and do not use oral contraceptives, for females who use oral contraceptives, for pregnant females, and for females in the postpartum period. To put the risk of developing a VTE into perspective: If 10,000 females who are not pregnant and do not use oral contraceptives are followed for one year, between 1 and 5 of these females will develop a VTE.

Figure 1: Likelihood of Developing a VTE

image-02
(click image for full-size original)

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.